Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

ClinicalTrials.gov ID: NCT01743651

Public ClinicalTrials.gov record NCT01743651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity. Eligible subjects will be removed from anti-spasticity medications for at least one week and then begin study drug treatment with daily doses increasing up to the target dose which will then be maintained for at least 12 weeks. A down-titration will then occur over two weeks.

Study identification

NCT ID
NCT01743651
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Enrollment
353 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2012
Primary completion
Mar 31, 2014
Completion
Mar 31, 2014
Last update posted
Apr 24, 2022

2012 – 2014

United States locations

U.S. sites
25
U.S. states
17
U.S. cities
23
Facility City State ZIP Site status
Osmotica Study Site-138 Cullman Alabama 35058
Osmotica Site-143 Long Beach California 92845
Osmotica Study Site-123 Aurora Colorado 80045
Osmotica Study Site-110 Bradenton Florida 34205
Osmotica Study Site-142 Maitland Florida 32751
Osmotica Study Site-119 Ormond Beach Florida 32174
Osmotica Study Site-120 Pompano Beach Florida 33060
Osmotica Study Site-109 Tampa Florida 33606
Osmotica Study Site-126 Northbrook Illinois 60096
Osmotica Study Site-108 Fort Wayne Indiana 46805
Osmotica Study Site-116 Lenexa Kansas 66214
Osmotica Study Site-124 Baltimore Maryland 21201
Osmotica Study Site-136 Springfield Massachusetts 01104
Osmotica Study Site-101 Ann Arbor Michigan 48104
Osmotica Study Site-115 Johnson City New York 13790
Osmotica Study Site-113 New York New York 10016
Osmotica Study Site-141 New York New York 10019
Osmotica Study Site-125 New York New York 10029
Osmotica Study Site-106 Charlotte North Carolina 28204
Osmotica Study Site-131 Cincinnati Ohio 45219
Osmotica Study Site-127 Pittsburgh Pennsylvania 15212
Osmotica Study Site-112 San Antonio Texas 78229
Osmotica Study Site-133 Salt Lake City Utah 84103
Osmotica Study Site-129 Seattle Washington 98122
Osmotica SIte-144 Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

Recently updated Spasticity trials

Other public records listing Spasticity. Sorted by last update posted; newest first. Not a recommendation.

All Spasticity trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01743651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 24, 2022 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01743651 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →